Autoantibodies to posttranslational modifications in rheumatoid arthritis

Mediators of Inflammation

Volumn 2014, Issue , 2014, Pages

  Burska, Agata N ^a   Hunt, Laura ^a   Boissinot, Marjorie ^a   Strollo, Rocky ^b   Ryan, Brent J ^c   Vital, Ed ^a   Nissim, Ahuva ^b   Winyard, Paul G ^d   Emery, Paul ^a   Ponchel, Frederique ^a  

^a UNIVERSITY OF LEEDS   (United Kingdom)

^b QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^c UNIVERSITY OF OXFORD   (United Kingdom)

^d UNIVERSITY OF EXETER MEDICAL SCHOOL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIGEN; ANTIOXIDANT; AUTOANTIBODY; BIOLOGICAL MARKER; CITRULLINE; OXYGEN; REACTIVE OXYGEN METABOLITE;

ANIMAL; B LYMPHOCYTE; CHEMISTRY; CYTOLOGY; HUMAN; IMMUNOLOGY; INFLAMMATION; METABOLISM; PROTEIN PROCESSING; RHEUMATOID ARTHRITIS;

ANIMALS; ANTIGENS; ANTIOXIDANTS; ARTHRITIS, RHEUMATOID; AUTOANTIBODIES; B-LYMPHOCYTES; BIOLOGICAL MARKERS; CITRULLINE; HUMANS; INFLAMMATION; OXYGEN; PROTEIN PROCESSING, POST-TRANSLATIONAL; REACTIVE OXYGEN SPECIES;

EID: 84899443521     PISSN: 09629351     EISSN: 14661861     Source Type: Journal    
DOI: 10.1155/2014/492873     Document Type: Review

References (255)

1. Silverman G. J., Weisman S., Rituximab therapy and autoimmune disorders: prospects for anti-B cell therapy. Arthritis & Rheumatism 2003 48 6 1484 1492 2-s2.0-0037638841 10.1002/art.10947 (Pubitemid 36682354)
2. Crotty S., Ahmed R., Immunological memory in humans. Seminars in Immunology 2004 16 3 197 203 2-s2.0-2342584151 10.1016/j.smim.2004.02.008 (Pubitemid 38569900)
3. Gourley T. S., Wherry E. J., Masopust D., Ahmed R., Generation and maintenance of immunological memory. Seminars in Immunology 2004 16 5 323 333 2-s2.0-7544236264 10.1016/j.smim.2004.08.013 (Pubitemid 39451802)
4. Radbruch A., Muehlinghaus G., Luger E. O., Inamine A., Smith K. G. C., Dörner T., Hiepe F., Competence and competition: the challenge of becoming a long-lived plasma cell. Nature Reviews Immunology 2006 6 10 741 750 2-s2.0-33749018225 10.1038/nri1886 (Pubitemid 44453460)
5. Burgoyne C. H., Field S. L., Brown A. K., Hensor E. M., English A., Bingham S. L., Verburg R., Fearon U., Lawson C. A., Hamlin P. J., Straszynski L., Veale D., Conaghan P., Hull M. A., van Laar J. M., Tennant A., Emery P., Isaacs J. D., Ponchel F., Abnormal T cell differentiation persists in patients with rheumatoid arthritis in clinical remission and predicts relapse. Annals of the Rheumatic Diseases 2008 67 6 750 757 2-s2.0-45149093251 10.1136/ard.2007. 073833 (Pubitemid 351829373)
6. Nissim A., Winyard P. G., Corrigall V., Fatah R., Perrett D., Panayi G., Chernajovsky Y., Generation of neoantigenic epitopes after posttranslational modification of type II collagen by factors present within the inflamed joint. Arthritis & Rheumatism 2005 52 12 3829 3838 2-s2.0-29144482654 10.1002/art.21479 (Pubitemid 41798221)
7. Marcinkiewicz J., Biedroń R., Maresz K., Kwaśny-Krochin B., Bobek M., Kontny E., Maśliński W., Chain B., Oxidative modification of type II collagen differentially affects its arthritogenic and tolerogenic capacity in experimental arthritis. Archivum Immunologiae et Therapiae Experimentalis 2004 52 4 284 291 2-s2.0-4944261959 (Pubitemid 39331162)
8. Anderton S. M., Post-translational modifications of self antigens: implications for autoimmunity. Current Opinion in Immunology 2004 16 6 753 758 2-s2.0-7044235838 10.1016/j.coi.2004.09.001 (Pubitemid 39423665)
9. Shi J., Knevel R., Suwannalai P., van der Linden M. P., Janssen G. M. C., van Veelen P. A., Levarht N. E. W., van der Helm-van Mil A. H. M., Cerami A., Huizinga T. W. J., Toes R. E. M., Trouw L. A., Autoantibodies recognizing carbamylated proteins are present in sera of patients with rheumatoid arthritis and predict joint damage. Proceedings of the National Academy of Sciences of the United States of America 2011 108 42 17372 17377 2-s2.0-80054806901 10.1073/pnas.1114465108
10. Eggleton P., Nissim A., Ryan B. J., Whiteman M., Winyard P. G., Detection and isolation of human serum autoantibodies that recognize oxidatively modified autoantigens. Free Radical Biology & Medicine 2013 57 79 91 10.1016/j.freeradbiomed.2012.11.006
11. Steinbrecher U. P., Fisher M., Witztum J. L., Curtiss L. K., Immunogenicity of homologous low density lipoprotein after methylation, ethylation, acetylation, or carbamylation: generation of antibodies specific for derivatized lysine. Journal of Lipid Research 1984 25 10 1109 1116 2-s2.0-0021691725 (Pubitemid 15207094)
12. Martinez-Gamboa L., Brezinschek H.-P., Burmester G. R., Dörner T., Immunopathologic role of B lymphocytes in rheumatoid arthritis: rationale of B cell-directed therapy. Autoimmunity Reviews 2006 5 7 437 442 2-s2.0-33747203086 10.1016/j.autrev.2006.02.004 (Pubitemid 44233402)
13. Bugatti S., Codullo V., Caporali R., Montecucco C., B cells in rheumatoid arthritis. Autoimmunity Reviews 2007 7 2 137 142 2-s2.0-36148969711 10.1016/j.autrev.2007.02.017 (Pubitemid 350116726)
14. Baka Z., György B., Géher P., Buzás E. I., Falus A., Nagy G., Citrullination under physiological and pathological conditions. Joint Bone Spine 2012 79 5 431 436 2-s2.0-84857332701 10.1016/j.jbspin.2012.01.008
15. Winyard P. G., Moody C. J., Jacob C., Oxidative activation of antioxidant defence. Trends in Biochemical Sciences 2005 30 8 453 461 2-s2.0-22744441812 10.1016/j.tibs.2005.06.001 (Pubitemid 41033241)
16. Karsdal M. A., Henriksen K., Leeming D. J., Woodworth T., Vassiliadis E., Bay-Jensen A.-C., Novel combinations of post-translational modification (PTM) neo-epitopes provide tissue-specific biochemical markers-are they the cause or the consequence of the disease? Clinical Biochemistry 2010 43 10-11 793 804 2-s2.0-77953706518 10.1016/j.clinbiochem.2010.03.015
17. Rodríguez-García J., Requena J. R., Rodríguez-Segade S., Increased concentrations of serum pentosidine in rheumatoid arthritis. Clinical Chemistry 1998 44 2 250 255 2-s2.0-0031910540 (Pubitemid 28087720)
18. Richardot P., Charni-Ben Tabassi N., Toh L., Marotte H., Bay-Jensen A.-C., Miossec P., Garnero P., Nitrated type III collagen as a biological marker of nitric oxide-mediated synovial tissue metabolism in osteoarthritis. Osteoarthritis and Cartilage 2009 17 10 1362 1367 2-s2.0-70349386224 10.1016/j.joca.2009.04.024
19. Reddy V. P., Obrenovich M. E., Atwood C. S., Perry G., Smith M. A., Involvement of Maillard reactions in Alzheimer disease. Neurotoxicity Research 2002 4 3 191 209 2-s2.0-0036080646 10.1080/1029840290007321 (Pubitemid 34679370)
20. Ishigami A., Ohsawa T., Hiratsuka M., Taguchi H., Kobayashi S., Saito Y., Murayama S., Asaga H., Toda T., Kimura N., Maruyama N., Abnormal accumulation of citrullinated proteins catalyzed by peptidylarginine deiminase in hippocampal extracts from patients with Alzheimer's disease. Journal of Neuroscience Research 2005 80 1 120 128 2-s2.0-20244368810 10.1002/jnr.20431 (Pubitemid 40577300)
21. Acharya N. K., Nagele E. P., Han M., Coretti N. J., DeMarshall C., Kosciuk M. C., Boulos P. A., Nagele R. G., Neuronal PAD4 expression and protein citrullination: possible role in production of autoantibodies associated with neurodegenerative disease. Journal of Autoimmunity 2012 38 4 369 380 2-s2.0-84860548076 10.1016/j.jaut.2012.03.004
22. Berlyne G., Carbamylated proteins and peptides in health and in uremia. Nephron 1998 79 2 125 130 2-s2.0-0031833309 10.1159/000045013 (Pubitemid 28256554)
23. Dobritzsch D., Lindh I., Uysal H., Nandakumar K. S., Burkhardt H., Schneider G., Holmdahl R., Crystal structure of an arthritogenic anticollagen immune complex. Arthritis & Rheumatism 2011 63 12 3740 3748 2-s2.0-82455212511 10.1002/art.30611
24. Burkhardt H., Sehnert B., Bockermann R., Engström Å., Kalden J. R., Holmdahl R., Humoral immune response to citrullinated collagen type II determinants in early rheumatoid arthritis. European Journal of Immunology 2005 35 5 1643 1652 2-s2.0-18844386764 10.1002/eji.200526000 (Pubitemid 40691444)
25. Snir O., Widhe M., Von Spee C., Lindberg J., Padyukov L., Lundberg K., Engström Å., Venables P. J., Lundeberg J., Holmdahl R., Klareskog L., Malmström V., Multiple antibody reactivities to citrullinated antigens in sera from patients with rheumatoid arthritis: association with HLA-DRB1 alleles. Annals of the Rheumatic Diseases 2009 68 5 736 743 2-s2.0-66149124137 10.1136/ard.2008.091355
26. Mydel P., Wang Z., Brisslert M., Hellvard A., Dahlberg L. E., Hazen S. L., Bokarewa M., Carbamylation-dependent activation of T cells: a novel mechanism in the pathogenesis of autoimmune arthritis. Journal of Immunology 2010 184 12 6882 6890 2-s2.0-77953627756 10.4049/jimmunol.1000075
27. Turunen S., Koivula M.-K., Risteli L., Risteli J., Anticitrulline antibodies can be caused by homocitrulline-containing proteins in rabbits. Arthritis & Rheumatism 2010 62 11 3345 3352 2-s2.0-78249272045 10.1002/art.27644
28. Uysal H., Bockermann R., Nandakumar K. S., Sehnert B., Bajtner E., Engström Å., Serre G., Burkhardt H., Thunnissen M. M. G. M., Holmdahl R., Structure and pathogenicity of antibodies specific for citrullinated collagen type II in experimental arthritis. The Journal of Experimental Medicine 2009 206 2 449 462 2-s2.0-63049101247 10.1084/jem.20081862
29. Kim W.-U., Cho M.-L., Jung Y. O., Min S.-Y., Park S.-W., Min D.-J., Yoon J.-H., Kim H.-Y., Type II collagen autoimmunity in rheumatoid arthritis. The American Journal of the Medical Sciences 2004 327 4 202 211 2-s2.0-1842682969 10.1097/00000441-200404000-00006 (Pubitemid 38480805)
30. Nandakumar K. S., Andrén M., Martinsson P., Bajtner E., Hellström S., Holmdahl R., Kleinau S., Induction of arthritis by single monoclonal IgG anti-collagen type II antibodies and enhancement of arthritis in mice lacking inhibitory Fc γ RIIB. European Journal of Immunology 2003 33 8 2269 2277 2-s2.0-0042476389 10.1002/eji.200323810 (Pubitemid 37010045)
31. Holmdahl R., Bockermann R., Bäcklund J., Yamada H., The molecular pathogenesis of collagen-induced arthritis in mice-a model for rheumatoid arthritis. Ageing Research Reviews 2002 1 1 135 147 2-s2.0-0036484325 10.1016/S0047-6374(01)00371-2 (Pubitemid 38344149)
32. Rowley M. J., Nandakumar K., Holmdahl R., The role of collagen antibodies in mediating arthritis. Modern Rheumatology 2008 18 5 429 441 2-s2.0-53549088056 10.1007/s10165-008-0080-x
33. Cho Y.-G., Cho M.-L., Min S.-Y., Kim H.-Y., Type II collagen autoimmunity in a mouse model of human rheumatoid arthritis. Autoimmunity Reviews 2007 7 1 65 70 2-s2.0-35548929833 10.1016/j.autrev.2007.08.001 (Pubitemid 350011068)
34. Croxford A. M., Whittingham S., McNaughton D., Nandakumar K. S., Holmdahl R., Rowley M. J., Type II collagen-specific antibodies induce cartilage damage in mice independent of inflammation. Arthritis & Rheumatism 2013 65 3 650 659 10.1002/art.37805
35. Rönnelid J., Wick M. C., Lampa J., Lindblad S., Nordmark B., Klareskog L., van Vollenhoven R. F., Longitudinal analysis of citrullinated protein/peptide antibodies (anti-CP) during 5 year follow up in early rheumatoid arthritis: anti-CP status predicts worse disease activity and greater radiological progression. Annals of the Rheumatic Diseases 2005 64 12 1744 1749 2-s2.0-27844610761 10.1136/ard.2004.033571 (Pubitemid 41667149)
36. Teng Y. O., Wheater G., Hogan V. E., Stocks P., Levarht E. N., Huizinga T. W. J., Toes R. E. M., van Laar J. M., Induction of long-term B-cell depletion in refractory rheumatoid arthritis patients preferentially affects autoreactive more than protective humoral immunity. Arthritis Research & Therapy 2012 14 2, article R57 2-s2.0-84857982104 10.1186/ar3770
37. Andriopoulos N. A., Mestecky J., Miller E. J., Bradley E. L., Antibodies to native and denatured collagens in sera of patients with rheumatoid arthritis. Arthritis & Rheumatism 1976 19 3 613 617 2-s2.0-0016955291
38. Strollo R., Ponchel F., Malmström V., Rizzo P., Bombardieri M., Wenham C. Y., Landy R., Perret D., Watt F., Corrigall V. M., Winyard P. G., Pozzilli P., Conaghan P. G., Panayi G. S., Klareskog L., Emery P., Nissim A., Autoantibodies to posttranslationally modified type II collagen as potential biomarkers for rheumatoid arthritis. Arthritis & Rheumatism 2013 65 7 1702 1712 10.1002/art.37964
39. Griffiths H. R., Is the generation of neo-antigenic determinants by free radicals central to the development of autoimmune rheumatoid disease? Autoimmunity Reviews 2008 7 7 544 549 2-s2.0-50949105388 10.1016/j.autrev.2008. 04.013
40. Sebbag M., Chapuy-Regaud S., Auger I., Petit-Texeira E., Clavel C., Nogueira L., Vincent C., Corńlis F., Roudier J., Serre G., Clinical and pathophysiological significance of the autoimmune response to citrullinated proteins in rheumatoid arthritis. Joint Bone Spine 2004 71 6 493 502 2-s2.0-10344230419 10.1016/j.jbspin.2004.07.004 (Pubitemid 39626716)
41. Young B. J., Mallya R. K., Leslie R. D., Anti-keratin antibodies in rheumatoid arthritis. British Medical Journal 1979 2 6182 97 99 2-s2.0-0018777143 (Pubitemid 9219480)
42. Kurki P., Aho K., Palosuo T., Heliovaara M., Immunopathology of rheumatoid arthritis. Arthritis & Rheumatism 1992 35 8 914 917 2-s2.0-0026681481 10.1002/art.1780350810
43. Sokolove J., Bromberg R., Deane K. D., Lahey L. J., Derber L. A., Chandra P. E., Edison J. D., Gilliland W. R., Tibshirani R. J., Norris J. M., Holers V. M., Robinson W. H., Autoantibody epitope spreading in the pre-clinical phase predicts progression to rheumatoid arthritis. PLoS ONE 2012 7 5 e35296 10.1371/journal.pone.0035296
44. Rantapää-Dahlqvist S., de Jong B. A. W., Berglin E., Hallmans G., Wadell G., Stenlund H., Sundin U., van Venrooij W. J., Antibodies against cyclic citrullinated peptide and IgA rheumatoid factor predict the development of rheumatoid arthritis. Arthritis & Rheumatism 2003 48 10 2741 2749 2-s2.0-18744430797 10.1002/art.11223 (Pubitemid 37280601)
45. Gomes-Daudrix V., Sebbag M., Girbal E., Vincent C., Simon M., Rakotoarivony J., Abbal M., Fournie B., Serre G., Immunoblotting detection of so-called 'antikeratin antibodies': a new assay for the diagnosis of rheumatoid arthritis. Annals of the Rheumatic Diseases 1994 53 11 735 742 2-s2.0-0027943049 (Pubitemid 24347501)
46. Vincent C., Simon M., Sebbag M., Girbal-Neuhauser E., Durieux J.-J., Cantagrel A., Fournié B., Mazières B., Serre G., Immunoblotting detection of autoantibodies to human epidermis filaggrin: a new diagnostic test for rheumatoid arthritis. The Journal of Rheumatology 1998 25 5 838 846 2-s2.0-0031944654 (Pubitemid 28210541)
47. Vincent C., de Keyser F., Masson-Bessière C., Sebbag M., Veys E. M., Serre G., Anti-perinuclear factor compared with the so called "antikeratin" antibodies and antibodies to human epidermis filaggrin, in the diagnosis of arthritides. Annals of the Rheumatic Diseases 1999 58 1 42 48 2-s2.0-0033065470 (Pubitemid 29112949)
48. Serre G., Autoantibodies to filaggrin/deiminated fibrin (AFA) are useful for the diagnosis and prognosis of rheumatoid arthritis, and are probably involved in the pathophysiology of the disease. Joint Bone Spine 2001 68 2 103 105 2-s2.0-0035070717 10.1016/S1297-319X(01)00259-7 (Pubitemid 32275146)
49. Vincent C., Nogueira L., Sebbag M., Chapuy-Regaud S., Arnaud M., Letourneur O., Rolland D., Fournié B., Cantagrel A., Jolivet M., Serre G., Detection of antibodies to deiminated recombinant rat filaggrin by enzyme-linked immunosorbent assay: a highly effective test for the diagnosis of rheumatoid arthritis. Arthritis & Rheumatism 2002 46 8 2051 2058 2-s2.0-0036676806 10.1002/art.10436
50. De Rycke L., Peene I., Hoffman I. E. A., Kruithof E., Union A., Meheus L., Lebeer K., Wyns B., Vincent C., Mielants H., Boullart L., Serre G., Veys E. M., de Keyser F., Rheumatoid factor and anticitrullinated protein antibodies in rheumatoid arthritis: diagnosis value, associations with radiological progression rate, and extra-articular manifestations. Annals of the Rheumatic Diseases 2004 63 12 1587 1593 2-s2.0-7044279878 10.1136/ard.2003.017574 (Pubitemid 39573686)
51. Cruyssen B. V., Cantaert T., Nogueira L., Clavel C., de Rycke L., Dendoven A., Sebag M., Deforce D., Vincent C., Elewaut D., Serre G., de Keyser F., Diagnostic value of anti-human citrullinated fibrinogen ELISA and comparison with four other anti-citrullinated protein assays. Arthritis Research & Therapy 2006 8 4, article R122 2-s2.0-70350554075 10.1186/ar2011
52. Nogueira L., Sebbag M., Vincent C., Arnaud M., Fournié B., Cantagrel A., Jolivet M., Serre G., Performance of two ELISAs for antifilaggrin autoantibodies, using either affinity purified or deiminated recombinant human filaggrin, in the diagnosis of rheumatoid arthritis. Annals of the Rheumatic Diseases 2001 60 9 882 887 2-s2.0-0034883518 (Pubitemid 32778179)
53. Schellekens G. A., Visser H., de Jong B. A., van den Hoogen F. H., Hazes J. M., Breedveld F. C., van Venrooij W. J., The diagnostic properties of rheumatoid arthritis antibodies recognizing a cyclic citrullinated peptide. Arthritis & Rheumatism 2000 43 1 155 163 (Pubitemid 30368225)
54. Goëb V., Jouen F., Gilbert D., Le Loët X., Tron F., Vittecoq O., Diagnostic and prognostic usefulness of antibodies to citrullinated peptides. Joint Bone Spine 2009 76 4 343 349 2-s2.0-67649814646 10.1016/j.jbspin.2008.12.006
55. Alenius G. M., Psoriatic arthritis-new insights give new options for treatment. Current Medicinal Chemistry 2007 14 3 359 366 2-s2.0-33847229419 10.2174/092986707779941104
56. Hendler A., Mulli T. K., Hughes F. J., Perrett D., Bombardieri M., Houri-Haddad Y., Weiss E. I., Nissim A., Involvement of autoimmunity in the pathogenesis of aggressive periodontitis. Journal of Dental Research 2010 89 12 1389 1394 2-s2.0-78650154719 10.1177/0022034510381903
57. Chapuy-Regaud S., Nogueira L., Clavel C., Sebbag M., Vincent C., Serre G., IgG subclass distribution of the rheumatoid arthritis-specific autoantibodies to citrullinated fibrin. Clinical & Experimental Immunology 2005 139 3 542 550 2-s2.0-14744288584 10.1111/j.1365-2249.2004.02708.x (Pubitemid 40333267)
58. Masson-Bessière C., Sebbag M., Girbal-Neuhauser E., Nogueira L., Vincent C., Senshu T., Serre G., The major synovial targets of the rheumatoid arthritis-specific antifilaggrin autoantibodies are deiminated forms of the-and β -chains of fibrin. The Journal of Immunology 2001 166 6 4177 4184 2-s2.0-0035869593 (Pubitemid 32224951)
59. Sebbag M., Moinard N., Auger I., Clavel C., Arnaud J., Nogueira L., Roudier J., Serre G., Epitopes of human fibrin recognized by the rheumatoid arthritis-specific autoantibodies to citrullinated proteins. European Journal of Immunology 2006 36 8 2250 2263 2-s2.0-33747447697 10.1002/eji.200535790 (Pubitemid 44251769)
60. Girbal-Neuhauser E., Durieux J.-J., Arnaud M., Dalbon P., Sebbag M., Vincent C., Simon M., Senshu T., Masson-Bessière C., Jolivet-Reynaud C., Jolivet M., Serre G., The epitopes targeted by the rheumatoid arthritis-associated antifilaggrin autoantibodies are posttranslationally generated on various sites of (pro) filaggrin by deimination of arginine residues. The Journal of Immunology 1999 162 1 585 594 2-s2.0-0032960781 (Pubitemid 29018970)
61. Roth E. B., Theander E., Londos E., Sandberg-Wollheim M., Larsson Å., Sjöberg K., Stenberg P., Pathogenesis of autoimmune diseases: antibodies against transglutaminase, peptidylarginine deiminase and protein-bound citrulline in primary Sjögren's syndrome, multiple sclerosis and Alzheimer's disease. Scandinavian Journal of Immunology 2008 67 6 626 631 2-s2.0-43549086375 10.1111/j.1365-3083.2008.02115.x (Pubitemid 351677420)
62. Moscarello M. A., Mastronardi F. G., Wood D. D., The role of citrullinated proteins suggests a novel mechanism in the pathogenesis of multiple sclerosis. Neurochemical Research 2007 32 2 251 256 2-s2.0-33846914679 10.1007/s11064-006-9144-5 (Pubitemid 46238870)
63. Baka Z., Barta P., Losonczy G., Krenács T., Pápay J., Szarka E., Sármay G., Babos F., Magyar A., Géher P., Buzás E. I., Nagy G., Specific expression of PAD4 and citrullinated proteins in lung cancer is not associated with anti-CCP antibody production. International Immunology 2011 23 6 405 414 2-s2.0-79957813556 10.1093/intimm/dxr026
64. Stadlera S. C., Vincentc C. T., Fedorove V. D., Patsialouf A., Cherringtong B. D., Wakshlagh J. J., Mohanani S., Zeej B. M., Zhangi X., Garciaj B. A., Condeelisf J. S., Brownk A. M. C., Coonrodi S. A., Allis C. D., Dysregulation of PAD4-mediated citrullination of nuclear GSK3 β activates TGF- β signaling and induces epithelial-to-mesenchymal transition in breast cancer cells. Proceedings of the National Academy of Sciences of the United States of America 2013 110 29 11851 11856 10.1073/pnas.1308362110
65. Foulquier C., Sebbag M., Clavel C., Chapuy-Regaud S., Al Badine R., Méchin M.-C., Vincent C., Nachat R., Yamada M., Takahara H., Simon M., Guerrin M., Serre G., Peptidyl arginine deiminase type 2 (PAD-2) and PAD-4 but not PAD-1, PAD-3, and PAD-6 are expressed in rheumatoid arthritis synovium in close association with tissue inflammation. Arthritis & Rheumatism 2007 56 11 3541 3553 2-s2.0-36049041609 10.1002/art.22983 (Pubitemid 350100687)
66. Romero V., Fert-Bober J., Nigrovic P. A., Darrah E., Haque U. J., Lee D. M., van Eyk J., Rosen A., Andrade F., Immune-mediated pore-forming pathways induce cellular hypercitrullination and generate citrullinated autoantigens in rheumatoid arthritis. Science Translational Medicine 2013 5 209 209ra150 10.1126/scitranslmed.3006869
67. Bang H., Egerer K., Gauliard A., Lüthke K., Rudolph P. E., Fredenhagen G., Berg W., Feist E., Burmester G.-R., Mutation and citrullination modifies vimentin to a novel autoantigen for rheumatoid arthritis. Arthritis & Rheumatism 2007 56 8 2503 2511 2-s2.0-34547785469 10.1002/art.22817 (Pubitemid 47237269)
68. Kinloch A., Tatzer V., Wait R., Peston D., Lundberg K., Donatien P., Moyes D., Taylor P. C., Venables P. J., Identification of citrullinated alpha-enolase as a candidate autoantigen in rheumatoid arthritis. Arthritis Research & Therapy 2005 7 6 R1421 R1429 2-s2.0-33644667809 10.1186/ar1845
69. van der Helm-van Mil A. H. M., Verpoort K. N., Breedveld F. C., Toes R. E. M., Huizinga T. W. J., Antibodies to citrullinated proteins and differences in clinical progression of rheumatoid arthritis. Arthritis Research & Therapy 2005 7 5 R949 R958 2-s2.0-27844575688 10.1186/ar1767
70. Jansen L. M., van Schaardenburg D., van der Horst-Bruinsma I. E., van de Stadt R. J., de Koning M. H. M. T., Dijkmans B. A. C., The predictive value of anti-cyclic citrullinated peptide antibodies in early arthritis. The Journal of Rheumatology 2003 30 8 1691 1695 2-s2.0-0042029646 (Pubitemid 36962444)
71. Syversen S. W., Gaarder P. I., Goll G. L., Ødegård S., Haavardsholm E. A., Mowinckel P., van der Heijde D., Landewé R., Kvien T. K., High anti-cyclic citrullinated peptide levels and an algorithm of four variables predict radiographic progression in patients with rheumatoid arthritis: results from a 10-year longitudinal study. Annals of the Rheumatic Diseases 2008 67 2 212 217 2-s2.0-38749113412 10.1136/ard.2006.068247 (Pubitemid 351183310)
72. Machold K. P., Stamm T. A., Nell V. P. K., Pflugbeil S., Aletaha D., Steiner G., Uffmann M., Smolen J. S., Very recent onset rheumatoid arthritis: clinical and serological patient characteristics associated with radiographic progression over the first years of disease. Rheumatology 2007 46 2 342 349 2-s2.0-33846691023 10.1093/rheumatology/kel237 (Pubitemid 46189798)
73. Syversen S. W., Gaarder P. I., Goll G. L., Ødegård S., Haavardsholm E. A., Mowinckel P., van der Heijde D., Landewé R., Kvien T. K., High anti-cyclic citrullinated peptide levels and an algorithm of four variables predict radiographic progression in patients with rheumatoid arthritis: results from a 10-year longitudinal study. Annals of the Rheumatic Diseases 2008 67 2 212 217 2-s2.0-38749113412 10.1136/ard.2006.068247 (Pubitemid 351183310)
74. Aubart F., Crestani B., Nicaise-Roland P., Tubach F., Bollet C., Dawidowicz K., Quintin E., Hayem G., Palazzo E., Meyer O., Chollet-Martin S., Dieudé P., High levels of anti-cyclic citrullinated peptide autoantibodies are associated with co-occurrence of pulmonary diseases with rheumatoid arthritis. The Journal of Rheumatology 2011 38 6 979 982 2-s2.0-79957876602 10.3899/jrheum.101261
75. Klareskog L., Stolt P., Lundberg K., Källberg H., Bengtsson C., Grunewald J., Rönnelid J., Harris H. E., Ulfgren A.-K., Rantapää-Dahlqvist S., Eklund A., Padyukov L., Alfredsson L., A new model for an etiology of rheumatoid arthritis: smoking may trigger HLA-DR (shared epitope)-restricted immune reactions to autoantigens modified by citrullination. Arthritis & Rheumatism 2006 54 1 38 46 2-s2.0-31044445025 10.1002/art.21575 (Pubitemid 43122184)
76. Vincent C., Serre G., Lapeyre F., Fournie B., Ayrolles C., Fournie A., Soleilhavoup J.-P., High diagnostic value in rheumatoid arthritis of antibodies to the stratum corneum of rat oesophagus epithelium, so-called 'antikeratin antibodies'. Annals of the Rheumatic Diseases 1989 48 9 712 722 2-s2.0-0024363736 (Pubitemid 19225042)
77. Berglin E., Johansson T., Sundin U., Jidell E., Wadell G., Hallmans G., Rantapää-Dahlqvist S., Radiological outcome in rheumatoid arthritis is predicted by presence of antibodies against cyclic citrullinated peptide before and at disease onset, and by IgA-RF at disease onset. Annals of the Rheumatic Diseases 2006 65 4 453 458 2-s2.0-33645116507 10.1136/ard.2005.041376
78. van Gaalen F. A., Linn-Rasker S. P., van Venrooij W. J., de Jong B. A., Breedveld F. C., Verweij C. L., Toes R. E. M., Huizinga T. W. J., Autoantibodies to cyclic citrullinated peptides predict progression to rheumatoid arthritis in patients with undifferentiated arthritis: a prospective cohort study. Arthritis & Rheumatism 2004 50 3 709 715 2-s2.0-1542283760 10.1002/art.20044 (Pubitemid 38326168)
79. Aletaha D., Neogi T., Silman A. J., Funovits J., Felson D. T., Bingham 3rd C. O., Birnbaum N. S., Burmester G. R., Bykerk V. P., Cohen M. D., Combe B., Costenbader K. H., Dougados M., Emery P., Ferraccioli G., Hazes J. M., Hobbs K., Huizinga T. W., Kavanaugh A., Kay J., Kvien T. K., Laing T., Mease P., Ménard H. A., Moreland L. W., Naden R. L., Pincus T., Smolen J. S., Stanislawska-Biernat E., Symmons D., Tak P. P., Upchurch K. S., Vencovsky J., Wolfe F., Hawker G., 2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Annals of the Rheumatic Diseases 2010 69 9 1580 1589 2-s2.0-77957262195 10.1136/ard.2010.138461
80. Modi S., Soejima M., Levesque M. C., The effect of targeted rheumatoid arthritis therapies on anti-citrullinated protein autoantibody levels and B cell responses. Clinical & Experimental Immunology 2013 173 1 8 17 10.1111/cei.12114
81. Mikuls T. R., O'Dell J. R., Stoner J. A., Parrish L. A., Arend W. P., Norris J. M., Holers V. M., Association of rheumatoid arthritis treatment response and disease duration with declines in serum levels of IgM rheumatoid factor and anti-cyclic citrullinated peptide antibody. Arthritis & Rheumatism 2004 50 12 3776 3782 2-s2.0-10444250299 10.1002/art.20659 (Pubitemid 39643924)
82. Braun-Moscovici Y., Markovits D., Zinder O., Schapira D., Rozin A., Ehrenburg M., Dain L., Hoffer E., Nahir A. M., Balbir-Gurman A., Anti-cyclic citrullinated protein antibodies as a predictor of response to anti-tumor necrosis factor- therapy in patients with rheumatoid arthritis. The Journal of Rheumatology 2006 33 3 497 500 2-s2.0-33644698605 (Pubitemid 43334571)
83. Chen H. A., Lin K. C., Chen C. H., Liao H. T., Wang H. P., Chang H. N., Tsai C. Y., Chou C.-T., The effect of etanercept on anti-cyclic citrullinated peptide antibodies and rheumatoid factor in patients with rheumatoid arthritis. Annals of the Rheumatic Diseases 2006 65 1 35 39 2-s2.0-29144519684 10.1136/ard.2005.038851 (Pubitemid 41815636)
84. Alessandri C., Priori R., Modesti M., Mancini R., Valesini G., The role of anti-cyclic cytrullinate antibodies testing in rheumatoid arthritis. Clinical Reviews in Allergy & Immunology 2008 34 1 45 49 2-s2.0-49349089773 10.1007/s12016-007-8023-4
85. Alessandri C., Bombardieri M., Papa N., Cinquini M., Magrini L., Tincani A., Valesini G., Decrease of anti-cyclic citrullinated peptide antibodies and rheumatoid factor following anti-TNF therapy (infliximab) in rheumatoid arthritis is associated with clinical improvement. Annals of the Rheumatic Diseases 2004 63 10 1218 1221 2-s2.0-1942440157 10.1136/ard.2003.014647 (Pubitemid 39273496)
86. Bobbio-Pallavicini F., Caporali R., Alpini C., Moratti R., Montecucco C., Predictive value of antibodies to citrullinated peptides and rheumatoid factors in anti-TNF- treated patients. Annals of the New York Academy of Sciences 2007 1109 1 287 295 2-s2.0-34848842839 10.1196/annals.1398.034 (Pubitemid 47511371)
87. Allanore Y., Sellam J., Batteux F., Job Deslandre C., Weill B., Kahan A., Induction of autoantibodies in refractory rheumatoid arthritis treated by infliximab. Clinical and Experimental Rheumatology 2004 22 6 756 758 2-s2.0-11044222894 (Pubitemid 40045539)
88. Atzeni F., Sarzi-Puttini P., Dell Acqua D., de Portu S., Cecchini G., Cruini C., Carrabba M., Meroni P. L., Adalimumab clinical efficacy is associated with rheumatoid factor and anti-cyclic citrullinated peptide antibody titer reduction: a one-year prospective study. Arthritis Research & Therapy 2006 8 1, article R3 2-s2.0-33747596519 10.1186/ar1851
89. Benucci M., Turchini S., Parrochi P., Boccaccini P., Manetti R., Cammelli E., Manfredi M., Correlation between different clinical activity and anti CC-P (anti-cyclic citrullinated peptide antibodies) titres in rheumatoid arthritis treated with three different tumor necrosis factors TNF- blockers. Recenti Progressi in Medicina 2006 97 3 134 139 2-s2.0-33646004315
90. Bos W. H., Bartelds G. M., Vis M., van der Horst A. R., Wolbink G. J., van de Stadt R. J., van Schaardenburg D., Dijkmans B. A. C., Lems W. F., Nurmohamed M. T., Aarden L., Hamann D., Preferential decrease in IgG4 anti-citrullinated protein antibodies during treatment with tumour necrosis factor blocking agents in patients with rheumatoid arthritis. Annals of the Rheumatic Diseases 2009 68 4 558 563 2-s2.0-65249143314 10.1136/ard.2008.088401
91. Cuchacovich M., Catalan D., Wainstein E., Gatica H., Soto L., Aravena O., Pesce B., Sabugo F., Aguillón J. C., Basal anti-cyclic citrullinated peptide (anti-CCP) antibody levels and a decrease in anti-CCP titres are associated with clinical response to adalimumab in rheumatoid arthritis. Clinical and Experimental Rheumatology 2008 26 6 1067 1073 2-s2.0-59149089521
92. Vis M., Bos W. H., Wolbink G., Voskuyl A. E., Twisk J. W. R., van de Stadt R., Hamann D., Dijkmans B. A. C., Lems W. F., IgM-rheumatoid factor, anti-cyclic citrullinated peptide, and anti-citrullinated human fibrinogen antibodies decrease during treatment with the tumor necrosis factor blocker infliximab in patients with rheumatoid arthritis. The Journal of Rheumatology 2008 35 3 425 428 2-s2.0-40649093607 (Pubitemid 351374415)
93. Taylor P., Gartemann J., Hsieh J., Creeden J., A systematic review of serum biomarkers anti-cyclic citrullinated Peptide and rheumatoid factor as tests for rheumatoid arthritis. Autoimmune Diseases 2011 2011 18 815038 10.4061/2011/815038
94. Bizzaro N., Antibodies to citrullinated peptides: a significant step forward in the early diagnosis of rheumatoid arthritis. Clinical Chemistry and Laboratory Medicine 2007 45 2 150 157 2-s2.0-33847121296 10.1515/CCLM.2007.027 (Pubitemid 46294678)
95. Bobbio-Pallavicini F., Alpini C., Caporali R., Avalle S., Bugatti S., Montecucco C., Autoantibody profile in rheumatoid arthritis during long-term infliximab treatment. Arthritis Research & Therapy 2004 6 3 R264 R272 2-s2.0-7044251465
96. De Rycke L., Verhelst X., Kruithof E., van Den Bosch F., Hoffman I. E. A., Veys E. M., de Keyser F., Rheumatoid factor, but not anti-cyclic citrullinated peptide antibodies, is modulated by infliximab treatment in rheumatoid arthritis. Annals of the Rheumatic Diseases 2005 64 2 299 302 2-s2.0-13244261140 10.1136/ard.2004.023523 (Pubitemid 40193631)
97. Nissinen R., Leirisalo-Repo M., Peltomaa R., Palosuo T., Vaarala O., Cytokine and chemokine receptor profile of peripheral blood mononuclear cells during treatment with infliximab in patients with active rheumatoid arthritis. Annals of the Rheumatic Diseases 2004 63 6 681 687 2-s2.0-2442649175 10.1136/ard.2003.008599 (Pubitemid 38658398)
98. Thurlings R. M., Vos K., Wijbrandts C. A., Zwinderman A. H., Gerlag D. M., Tak P. P., Synovial tissue response to rituximab: mechanism of action and identification of biomarkers of response. Annals of the Rheumatic Diseases 2008 67 7 917 925 2-s2.0-38149044612 10.1136/ard.2007.080960 (Pubitemid 351956651)
99. Cambridge G., Leandro M. J., Edwards J. C. W., Ehrenstein M. R., Salden M., Bodman-Smith M., Webster A. D. B., Serologic changes following B lymphocyte depletion therapy for rheumatoid arthritis. Arthritis & Rheumatism 2003 48 8 2146 2154 2-s2.0-0041571732 10.1002/art.11181 (Pubitemid 36959194)
100. Kormelink T. G., Tekstra J., Thurlings R. M., Boumans M. H. J., Vos K., Tak P. P., Bijlsma J. W. J., Lafeber F. P. J. G., Redegeld F. A., van Roon J. A. G., Decrease in immunoglobulin free light chains in patients with rheumatoid arthritis upon rituximab (anti-CD20) treatment correlates with decrease in disease activity. Annals of the Rheumatic Diseases 2010 69 12 2137 2144 2-s2.0-78649748637 10.1136/ard.2009.126441
101. Rosengren S., Wei N., Kalunian K. C., Zvaifler N. J., Kavanaugh A., Boyle D. L., Elevated autoantibody content in rheumatoid arthritis synovia with lymphoid aggregates and the effect of rituximab. Arthritis Research & Therapy 2008 10 5, article R105 2-s2.0-52449085305 10.1186/ar2497
102. Toubi E., Kessel A., Slobodin G., Boulman N., Pavlotzky E., Zisman D., Rozenbaum M., Rosner I., Changes in macrophage function after rituximab treatment in patients with rheumatoid arthritis. Annals of the Rheumatic Diseases 2007 66 6 818 820 2-s2.0-34249795160 10.1136/ard.2006.062505 (Pubitemid 46846705)
103. Teng Y., Verburg R. J., Verpoort K. N., Diepenhorst G. M. P., Bajema I. M., van Tol M. J. D., Jol-van der Zijde E. C. M., Toes R. E. M., Huizinga T. W. J., van Laar J. M., Differential responsiveness to immunoablative therapy in refractory rheumatoid arthritis is associated with level and avidity of anti-cyclic citrullinated protein autoantibodies: a case study. Arthritis Research & Therapy 2007 9 5, article R106 2-s2.0-36849066403 10.1186/ar2309 (Pubitemid 350226902)
104. Jaisson S., Pietrement C., Gillery P., Carbamylation-derived products: bioactive compounds and potential biomarkers in chronic renal failure and atherosclerosis. Clinical Chemistry 2011 57 11 1499 1505 2-s2.0-80055078220 10.1373/clinchem.2011.163188
105. Jaisson S., Gillery P., Evaluation of nonenzymatic posttranslational modification-derived products as biomarkers of molecular aging of proteins. Clinical Chemistry 2010 56 9 1401 1412 2-s2.0-77956389018 10.1373/clinchem.2010. 145201
106. Wang Z., Nicholls S. J., Rodriguez E. R., Kummu O., Hörkkö S., Barnard J., Reynolds W. F., Topol E. J., DiDonato J. A., Hazen S. L., Protein carbamylation links inflammation, smoking, uremia and atherogenesis. Nature Medicine 2007 13 10 1176 1184 2-s2.0-34948834705 10.1038/nm1637 (Pubitemid 47530630)
107. Golemi D., Maveyraud L., Vakulenko S., Samama J.-P., Mobashery S., Critical involvement of a carbamylated lysine in catalytic function of class D β -lactamases. Proceedings of the National Academy of Sciences of the United States of America 2001 98 25 14280 14285 2-s2.0-0035807996 10.1073/pnas.241442898 (Pubitemid 33121383)
108. Kraus L. M., Gaber L., Handorf C. R., Marti H.-P., Kraus Jr.A.P., Carbamoylation of glomerular and tubular proteins in patients with kidney failure: a potential mechanism of ongoing renal damage. Swiss Medical Weekly 2001 131 11-12 139 145 2-s2.0-0035941951 (Pubitemid 32246498)
109. Higashi S., Miyazaki K., Reactive site-modified tissue inhibitor of metalloproteinases-2 inhibits the cell-mediated activation of progelatinase A. Journal of Biological Chemistry 1999 274 15 10497 10504 2-s2.0-0033537943 10.1074/jbc.274.15.10497 (Pubitemid 29180928)
110. Oimomi M., Hatanaka H., Yoshimura Y., Carbamylation of insulin and its biological activity. Nephron 1987 46 1 63 66 2-s2.0-0023093020 (Pubitemid 17057039)
111. Grande F., Grisolia S., Diederich D., On the biological and chemical reactivity of carbamylated glucagon. Proceedings of the Society for Experimental Biology and Medicine 1972 139 3 855 860 2-s2.0-0015305057
112. Ishikawa K., Hatanaka H., Kawasaki T., Studies on the modification of hormones in patients with renal failure and clinical evaluation-with reference to carbamylated ACTH and insulin. Nihon Jinzo Gakkai Shi 1985 27 11 1605 1609 2-s2.0-0022349921 (Pubitemid 16193032)
113. Coleman T. R., Westenfelder C., Tögel F. E., Yang Y., Hu Z., Swenson L., Leuvenink H. G. D., Ploeg R. J., D'Uscio L. V., Katusic Z. S., Ghezzi P., Zanetti A., Kaushansky K., Fox N. E., Cerami A., Brines M., Cytoprotective doses of erythropoietin or carbamylated erythropoietin have markedly different procoagulant and activities. Proceedings of the National Academy of Sciences of the United States of America 2006 103 15 5965 5970 2-s2.0-33645827977 10.1073/pnas.0601377103
114. Lippincott J., Apostol I., Carbamylation of cysteine: a potential artifact in peptide mapping of hemoglobins in the presence of urea. Analytical Biochemistry 1999 267 1 57 64 2-s2.0-0033081236 10.1006/abio.1998.2970 (Pubitemid 29061806)
115. Jaisson S., Delevallée-Forte C., Touré F., Rieu P., Garnotel R., Gillery P., Carbamylated albumin is a potent inhibitor of polymorphonuclear neutrophil respiratory burst. FEBS Letters 2007 581 7 1509 1513 2-s2.0-33947501680 10.1016/j.febslet.2007.03.008 (Pubitemid 46463961)
116. Jaisson S., Larreta-Garde V., Bellon G., Hornebeck W., Garnotel R., Gillery P., Carbamylation differentially alters type I collagen sensitivity to various collagenases. Matrix Biology 2007 26 3 190 196 2-s2.0-33947263742 10.1016/j.matbio.2006.10.008 (Pubitemid 46420512)
117. Jaisson S., Lorimier S., Ricard-Blum S., Sockalingum G. D., Delevallée-Forte C., Kegelaer G., Manfait M., Garnotel R., Gillery P., Impact of carbamylation on type I collagen conformational structure and its ability to activate human polymorphonuclear neutrophils. Chemistry & Biology 2006 13 2 149 159 2-s2.0-32844456397 10.1016/j.chembiol.2005.11.005 (Pubitemid 43255587)
118. Scinocca M., Bell D. A., Racapé M., Joseph R., Shaw G., McCormick J. K., Gladman D. D., Pope J., Barra L., Cairns E., Antihomocitrullinated fibrinogen antibodies are specific to rheumatoid arthritis and frequently bind citrullinated proteins/peptides. The Journal of Rheumatology 2014 41 2 270 279 10.3899/jrheum.130742 130742
119. Sirpal S., Myeloperoxidase-mediated lipoprotein carbamylation as a mechanistic pathway for atherosclerotic vascular disease. Clinical Science 2009 116 9 681 695 2-s2.0-66949165904 10.1042/CS20080322
120. Basnakian A. G., Shah S. V., Ok E., Altunel E., Apostolov E. O., Carbamylated LDL. Advances in Clinical Chemistry 2010 51 25 52 2-s2.0-77955900040 10.1016/S0065-2423(10)51002-3
121. Apostolov E. O., Basnakian A. G., Ok E., Shah S. V., Carbamylated low-density lipoprotein: nontraditional risk factor for cardiovascular events in patients with chronic kidney disease. Journal of Renal Nutrition 2012 22 1 134 138 2-s2.0-84855168560 10.1053/j.jrn.2011.10.023
122. Apostolov E. O., Shah S. V., Ok E., Basnakian A. G., Carbamylated low-density lipoprotein induces monocyte adhesion to endothelial cells through intercellular adhesion molecule-1 and vascular cell adhesion molecule-1. Arteriosclerosis, Thrombosis, and Vascular Biology 2007 27 4 826 832 2-s2.0-34247223322 10.1161/01.ATV.0000258795.75121.8a (Pubitemid 46606713)
123. Apostolov E. O., Ray D., Savenka A. V., Shah S. V., Basnakian A. G., Chronic uremia stimulates LDL carbamylation and atherosclerosis. Journal of the American Society of Nephrology 2010 21 11 1852 1857 2-s2.0-78149354063 10.1681/ASN.2010040365
124. Swaminathan S., Shah S. V., Novel inflammatory mechanisms of accelerated atherosclerosis in kidney disease. Kidney International 2011 80 5 453 463 2-s2.0-84857086983
125. Garnotel R., Sabbah N., Jaisson S., Gillery P., Enhanced activation of and increased production of matrix metalloproteinase-9 by human blood monocytes upon adhering to carbamylated collagen. FEBS Letters 2004 563 1-3 13 16 2-s2.0-1842737769 10.1016/S0014-5793(04)00233-9 (Pubitemid 38471566)
126. Bang H., Karl K., Anette F., Eugen B., Gerd R., Carbamoylation of vimentin in patients with rheumatoid arthritis: identification of a novel protein modification with a possible link to disease pathogenesis. Arthritis & Rheumatism 2011 63 supplement 10, article 1745
127. Hill J. A., Southwood S., Sette A., Jevnikar A. M., Bell D. A., Cairns E., Cutting edge: the conversion of arginine to citrulline allows for a high-affinity peptide interaction with the rheumatoid arthritis-associated HLA-DRB10401 MHC class II molecule. The Journal of Immunology 2003 171 2 538 541 2-s2.0-0038107566 (Pubitemid 36871358)
128. Hill J. A., Bell D. A., Brintnell W., Yue D., Wehrli B., Jevnikar A. M., Lee D. M., Hueber W., Robinson W. H., Cairns E., Arthritis induced by posttranslationally modified (citrullinated) fibrinogen in DR4-IE transgenic mice. The Journal of Experimental Medicine 2008 205 4 967 979 2-s2.0-42249098465 10.1084/jem.20072051 (Pubitemid 351549891)
129. Shi J., van de Stadt L. A., Levarht E. W., Huizinga T. W., Toes R. E., Trouw L. A., van Schaardenburg D., Brief Report: anti-carbamylated protein antibodies are present in arthralgia patients and predict the development of rheumatoid arthritis. Arthritis & Rheumatism 2013 65 4 911 915 10.1002/art.37830
130. Willemze A., Toes R. E., Huizinga T. W., Trouw L. A., New biomarkers in rheumatoid arthritis. The Netherlands Journal of Medicine 2012 70 9 392 399
131. van Dongen H., van Aken J., Lard L. R., Visser K., Ronday H. K., Hulsmans H. M. J., Speyer I., Westedt M.-L., Peeters A. J., Allaart C. F., Toes R. E. M., Breedveld F. C., Huizinga T. W. J., Efficacy of methotrexate treatment in patients with probable rheumatoid arthritis: a double-blind, randomized, placebo-controlled trial. Arthritis & Rheumatism 2007 56 5 1424 1432 2-s2.0-34248512220 10.1002/art.22525 (Pubitemid 46764069)
132. van der Helm-van Mil A. H. M., Cessie S. L., van Dongen H., Breedveld F. C., Toes R. E. M., Huizinga T. W. J., A prediction rule for disease outcome in patients with recent-onset undifferentiated arthritis: how to guide individual treatment decisions. Arthritis & Rheumatism 2007 56 2 433 440 2-s2.0-33847009428 10.1002/art.22380
133. 2B in vivo requires the activity of protein L-isoaspartate O -methyltransferase, a putative protein repair enzyme. Journal of Biological Chemistry 2001 276 40 37161 37165 2-s2.0-0035813128 10.1074/jbc.M106682200
134. Griffiths H. R., Møller L., Bartosz G., Bast A., Bertoni-Freddari C., Collins A., Cooke M., Coolen S., Haenen G., Hoberg A.-M., Loft S., Lunec J., Olinski R., Parry J., Pompella A., Poulsen H., Verhagen H., Astley S. B., Biomarkers. Molecular Aspects of Medicine 2002 23 1-3 101 208 2-s2.0-3042656269 10.1016/S0098-2997(02)00017-1 (Pubitemid 34669882)
135. Griffiths H. R., Lunec J., Effects of reactive oxygen species on immunoglobulin G function. Molecular Aspects of Medicine 1991 12 2 107 119 2-s2.0-0026024172 10.1016/0098-2997(91)90006-8
136. Dai L., Lamb D. J., Leake D. S., Kus M. L., Jones H. W., Morris C. J., Winyard P. G., Evidence for oxidised low density lipoprotein in synovial fluid from rheumatoid arthritis patients. Free Radical Research 2000 32 6 479 486 2-s2.0-0034095193 (Pubitemid 30241350)
137. Kitas G. D., Erb N., Tackling ischaemic heart disease in rheumatoid arthritis. Rheumatology 2003 42 5 607 613 2-s2.0-0043280989 10.1093/ rheumatology/keg175 (Pubitemid 37220867)
138. Kaur H., Halliwell B., Evidence for nitric oxide-mediated oxidative damage in chronic inflammation nitrotyrosine in serum and synovial fluid from rheumatoid patients. FEBS Letters 1994 350 1 9 12 2-s2.0-0027930057 10.1016/0014-5793(94)00722-5 (Pubitemid 24261386)
139. Winyard P. G., Ryan B., Eggleton P., Nissim A., Taylor E., Faro M. L., Burkholz T., Szabó-Taylor K. E., Fox B., Viner N., Haigh R. C., Benjamin N., Jones A. M., Whiteman M., Measurement and meaning of markers of reactive species of oxygen, nitrogen and sulfur in healthy human subjects and patients with inflammatory joint disease. Biochemical Society Transactions 2011 39 5 1226 1232 2-s2.0-80053360921 10.1042/BST0391226
140. Adams L. E., Roberts S. M., Donovan-Brand R., Zimmer H., Hess E. V., Study of procainamide hapten-specific antibodies in rabbits and humans. International Journal of Immunopharmacology 1993 15 8 887 897 2-s2.0-0027431708 10.1016/0192-0561(93)90006-K (Pubitemid 23347779)
141. Raza K., Breese M., Nightingale P., Kumar K., Potter T., Carruthers D. M., Situnayake D., Gordon C., Buckley C. D., Salmon M., Kitas G. D., Predictive value of antibodies to cyclic citrullinated peptide in patients with very early inflammatory arthritis. The Journal of Rheumatology 2005 32 2 231 238 2-s2.0-13444265935 (Pubitemid 40209120)
142. Aswad D. W., Paranandi M. V., Schurter B. T., Isoaspartate in peptides and proteins: formation, significance, and analysis. Journal of Pharmaceutical and Biomedical Analysis 2000 21 6 1129 1136 2-s2.0-0033988464 10.1016/S0731-7085(99)00230-7 (Pubitemid 30001541)
143. Ingrosso D., D'Angelo S., di Carlo E., Perna A. F., Zappia V., Galletti P., Increased methyl esterification of altered aspartyl residues erythrocyte membrane proteins in response to oxidative stress. European Journal of Biochemistry 2000 267 14 4397 4405 2-s2.0-0033926856 10.1046/j.1432-1327.2000. 01485.x (Pubitemid 30461072)
144. Mamula M. J., Gee R. J., Elliott J. I., Sette A., Southwood S., Jones P.-J., Blier P. R., Isoaspartyl post-translational modification triggers autoimmune responses to self-proteins. Journal of Biological Chemistry 1999 274 32 22321 22327 2-s2.0-0033529490 10.1074/jbc.274.32.22321 (Pubitemid 29379266)
145. Yang M.-L., Doyle H. A., Gee R. J., Lowenson J. D., Clarke S., Lawson B. R., Aswad D. W., Mamula M. J., Intracellular protein modification associated with altered T cell functions in autoimmunity. The Journal of Immunology 2006 177 7 4541 4549 2-s2.0-33749143447 (Pubitemid 44469785)
146. Pattison D. J., Winyard P. G., Dietary antioxidants in inflammatory arthritis: do they have any role in etiology or therapy? Nature Clinical Practice Rheumatology 2008 4 11 590 596 2-s2.0-59149095775 10.1038/ncprheum0920
147. Kirkham P. A., Caramori G., Casolari P., Papi A. A., Edwards M., Shamji B., Triantaphyllopoulos K., Hussain F., Pinart M., Khan Y., Heinemann L., Stevens L., Yeadon M., Barnes P. J., Chung K. F., Adcock I. M., Oxidative stress-induced antibodies to carbonyl-modified protein correlate with severity of chronic obstructive pulmonary disease. American Journal of Respiratory and Critical Care Medicine 2011 184 7 796 802 2-s2.0-80053428842 10.1164/rccm.201010-1605OC
148. Al-Shobaili H. A., Robaee A. A. A., Alzolibani A., Khan M. I., Rasheed Z., Hydroxyl radical modification of Immunoglobulin G generated cross-reactive antibodies: its potential role in systemic lupus erythematosus. Clinical Medicine Insights 2011 4 11 19 2-s2.0-79958171114 10.4137/CMAMD.S6793
149. Chiurchiù V., Maccarrone M., Chronic inflammatory disorders and their redox control: from molecular mechanisms to therapeutic opportunities. Antioxidants and Redox Signaling 2011 15 9 2605 2641 2-s2.0-80053004011 10.1089/ars.2010.3547
150. Blough N. V., Zafiriou O. C., Reaction of superoxide with nitric oxide to form peroxonitrite in alkaline aqueous solution. Inorganic Chemistry 1985 24 22 3502 3504 2-s2.0-33845378793
151. Sandhu J. K., Robertson S., Birnboim H. C., Goldstein R., Distribution of protein nitrotyrosine in synovial tissues of patients with rheumatoid arthritis and osteoarthritis. The Journal of Rheumatology 2003 30 6 1173 1181 2-s2.0-0037981344 (Pubitemid 36666337)
152. Khan F., Siddiqui A. A., Prevalence of anti-3-nitrotyrosine antibodies in the joint synovial fluid of patients with rheumatoid arthritis, osteoarthritis and systemic lupus erythematosus. Clinica Chimica Acta 2006 370 1-2 100 107 2-s2.0-33746482187 10.1016/j.cca.2006.01.020 (Pubitemid 44137283)
153. Singh R., Barden A., Mori T., Beilin L., Advanced glycation end-products: a review. Diabetologia 2001 44 2 129 146 2-s2.0-0035135246 10.1007/ s001250051591 (Pubitemid 32156196)
154. Ligier S., Fortin P., Newkirk M., A new antibody in rheumatoid arthritis targeting glycated IgG: IgM anti-IgG-AGE. Rheumatology 1998 37 12 1307 1314 2-s2.0-0032415432
155. Viguet-Carrin S., Roux J. P., Arlot M. E., Merabet Z., Leeming D. J., Byrjalsen I., Delmas P. D., Bouxsein M. L., Contribution of the advanced glycation end product pentosidine and of maturation of type I collagen to compressive biomechanical properties of human lumbar vertebrae. Bone 2006 39 5 1073 1079 2-s2.0-33749518488 10.1016/j.bone.2006.05.013 (Pubitemid 44528385)
156. Drinda S., Franke S., Canet C. C., Petrow P., Bräuer R., Hüttich C., Stein G., Hein G., Identification of the advanced glycation end products N ε -carboxymethyllysine in the synovial tissue of patients with rheumatoid arthritis. Annals of the Rheumatic Diseases 2002 61 6 488 492 2-s2.0-0036098608 10.1136/ard.61.6.488 (Pubitemid 34539089)
157. Drinda S., Franke S., Rüster M., Petrow P., Pullig O., Stein G., Hein G., Identification of the receptor for advanced glycation end products in synovial tissue of patients with rheumatoid arthritis. Rheumatology International 2005 25 6 411 413 2-s2.0-23944517386 10.1007/s00296-004-0456-y (Pubitemid 41186907)
158. Chen J. R., Takahashi M., Suzuki M., Kushida K., Miyamoto S., Inoue T., Comparison of the concentrations of pentosidine in the synovial fluid, serum and urine of patients with rheumatoid arthritis and osteoarthritis. Rheumatology 1999 38 12 1275 1278 2-s2.0-0032761646
159. Stamp L. K., Khalilova I., Tarr J. M., Senthilmohan R., Turner R., Haigh R. C., Winyard P. G., Kettle A. J., Myeloperoxidase and oxidative stress in rheumatoid arthritis. Rheumatology 2012 51 10 1796 1803 10.1093/rheumatology/ kes193
160. Bergt C., Fu X., Huq N. P., Kao J., Heinecke J. W., Lysine residues direct the chlorination of tyrosines in YXXK motifs of apolipoprotein A-I when hypochlorous acid oxidizes high density lipoprotein. Journal of Biological Chemistry 2004 279 9 7856 7866 2-s2.0-1542289811 10.1074/jbc.M309046200 (Pubitemid 38294672)
161. Dai L., Zhang Z., Winyard P. G., Gaffney K., Jones H., Blake D. R., Morris C. J., A modified form of low-density lipoprotein with increased electronegative charge is present in rheumatoid arthritis synovial fluid. Free Radical Biology and Medicine 1996 22 4 705 710 2-s2.0-0031019339 10.1016/S0891-5849(96)00389-9 (Pubitemid 27043407)
162. Hitchon C. A., El-Gabalawy H. S., Oxidation in rheumatoid arthritis. Arthritis Research & Therapy 2004 6 6 265 278 2-s2.0-8544232149 10.1186/ar1447 (Pubitemid 39490014)
163. Newkirk M. M., LePage K., Niwa T., Rubin L., Advanced glycation endproducts (AGE) on IgG, a target for circulating antibodies in North American Indians with rheumatoid arthritis (RA). Cellular and Molecular Biology 1998 44 7 1129 1138 2-s2.0-0032201230
164. Newkirk M. M., Goldbach-Mansky R., Lee J., Hoxworth J., McCoy A., Yarboro C., Klippel J., El-Gabalawy H. S., Advanced glycation end-product (AGE)-damaged IgG and IgM autoantibodies to IgG-AGE in patients with early synovitis. Arthritis Research & Therapy 2003 5 2 R82 R90 2-s2.0-0242273355 10.1186/ar622
165. Grinnell S., Yoshida K., Jasin H. E., Responses of lymphocytes of patients with rheumatoid arthritis to IgG modified by oxygen radicals or peroxynitrite. Arthritis & Rheumatism 2005 52 1 80 83 2-s2.0-12344279824 10.1002/art.20760 (Pubitemid 40129235)
166. Kurien B. T., Scofield R. H., Autoimmunity and oxidatively modified autoantigens. Autoimmunity Reviews 2008 7 7 567 573 2-s2.0-50949098933 10.1016/j.autrev.2008.04.019
167. Jaswal S., Mehta H. C., Sood A. K., Kaur J., Antioxidant status in rheumatoid arthritis and role of antioxidant therapy. Clinica Chimica Acta 2003 338 1-2 123 129 2-s2.0-0344154565 10.1016/j.cccn.2003.08.011 (Pubitemid 37456698)
168. Bailey A. J., Sims T. J., Avery N. C., Halligan E. P., Non-enzymic glycation of fibrous collagen: reaction produces of glucose and ribose. Biochemical Journal 1995 305 2 385 390 2-s2.0-0028873846
169. Liao K. P., Gunnarsson M., Källberg H., Ding B., Plenge R. M., Padyukov L., Karlson E. W., Klareskog L., Askling J., Alfredsson L., Specific association of type 1 diabetes mellitus with anti-cyclic citrullinated peptide-positive rheumatoid arthritis. Arthritis & Rheumatism 2009 60 3 653 660 2-s2.0-61649105598 10.1002/art.24362
170. Lemarechal H., Allanore Y., Chenevier-Gobeaux C., Kahan A., Ekindjian O. G., Borderie D., Serum protein oxidation in patients with rheumatoid arthritis and effects of infliximab therapy. Clinica Chimica Acta 2006 372 1-2 147 153 2-s2.0-33747824192 10.1016/j.cca.2006.04.002 (Pubitemid 44286769)
171. Kageyama Y., Takahashi M., Ichikawa T., Torikai E., Nagano A., Reduction of oxidative stress marker levels by anti-TNF- antibody, infliximab, in patients with rheumatoid arthritis. Clinical and Experimental Rheumatology 2008 26 1 73 80 2-s2.0-40749105734 (Pubitemid 351385258)
172. Kageyama Y., Takahashi M., Nagafusa T., Torikai E., Nagano A., Etanercept reduces the oxidative stress marker levels in patients with rheumatoid arthritis. Rheumatology International 2008 28 3 245 251 2-s2.0-37249048791 10.1007/s00296-007-0419-1 (Pubitemid 350265468)
173. Túnez I., Feijóo M., Huerta G., Montilla P., Muñoz E., Ruíz A., Collantes E., The effect of infliximab on oxidative stress in chronic inflammatory joint disease. Current Medical Research and Opinion 2007 23 6 1259 1267 2-s2.0-34347209779 10.1185/030079907X187955 (Pubitemid 46998435)
174. Grootveld M., Henderson E. B., Farrell A., Blake D. R., Parkes H. G., Haycock P., Oxidative damage to hyaluronate and glucose in synovial fluid during exercise of the inflamed rheumatoid joint. Detection of abnormal low-molecular-mass metabolites by proton-nmr spectroscopy. Biochemical Journal 1991 273 2 459 467 2-s2.0-0026025865
175. Rowley D., Gutteridge J. M. C., Blake D., Lipid peroxidation in rheumatoid arthritis-thiobarbituric acid-reactive material and catalytic iron salts in synovial fluid from rheumatoid patients. Clinical Science 1984 66 6 691 695 2-s2.0-0021349664 (Pubitemid 14145923)
176. Taysi S., Polat F., Gul M., Sari R., Bakan E., Lipid peroxidation, some extracellular antioxidants, and antioxidant enzymes in serum of patients with rheumatoid arthritis. Rheumatology International 2002 21 5 200 204 2-s2.0-0036192815 10.1007/s00296-001-0163-x (Pubitemid 34209121)
177. Lourida E. S., Georgiadis A. N., Papavasiliou E. C., Papathanasiou A. I., Drosos A. A., Tselepis A. D., Patients with early rheumatoid arthritis exhibit elevated autoantibody titers against mildly oxidized low-density lipoprotein and exhibit decreased activity of the lipoprotein-associated phospholipase A2. Arthritis Research & Therapy 2007 9 1, article R19 2-s2.0-34247574624 10.1186/ar2129
178. Dalle-Donne I., Rossi R., Giustarini D., Milzani A., Colombo R., Protein carbonyl groups as biomarkers of oxidative stress. Clinica Chimica Acta 2003 329 1-2 23 38 2-s2.0-0037363715 10.1016/S0009-8981(03)00003-2 (Pubitemid 36187411)
179. Henrotin Y., Bruckner P., Pujol J.-P., The role of reactive oxygen species in homeostasis and degradation of cartilage. Osteoarthritis and Cartilage 2003 11 10 747 755 2-s2.0-0141504018 10.1016/S1063-4584(03)00150-X (Pubitemid 37184493)
180. Winterbourn C. C., Kettle A. J., Biomarkers of myeloperoxidase-derived hypochlorous acid. Free Radical Biology and Medicine 2000 29 5 403 409 2-s2.0-0034282230 10.1016/S0891-5849(00)00204-5
181. Laczik R., Szodoray P., Veres K., Szomják E., Csípõ I., Sipka S., Shoenfeld Y., Szekanecz Z., Soltész P., Assessment of IgG antibodies to oxidized LDL in patients with acute coronary syndrome. Lupus 2011 20 7 730 735 2-s2.0-79957604404 10.1177/0961203311398884
182. Thromb V. F., Lewis A. Conner Memorial Lecture. Mechanisms leading to myocardial infarction: insights from studies of vascular biology. Circulation 1994 90 4 I 2126 2146 2-s2.0-0028519887 10.1161/01.CIR.90.4.2126
183. Cvetkovic J., Wållberg-Jonsson S., Ahmed E., Rantapää- Dahlqvist S., Lefvert A. K., Increased levels of autoantibodies against copper-oxidized low density lipoprotein, malondialdehyde-modified low density lipoprotein and cardiolipin in patients with rheumatoid arthritis. Rheumatology 2002 41 9 988 995 2-s2.0-0036735162
184. Wu R., Svenungsson E., Gunnarsson I., Andersson B., Lundberg I., Schäfer Elinder L., Frostegård J., Antibodies against lysophosphatidylcholine and oxidized LDL in patients with SLE. Lupus 1999 8 2 142 150 2-s2.0-0032939973 (Pubitemid 29103601)
185. Hayem G., Nicaise-Roland P., Palazzo E., de Bandt M., Tubach F., Weber M., Meyer O., Anti-oxidized low-density-lipoprotein (OxLDL) antibodies in systemic lupus erythematosus with and without antiphospholipid syndrome. Lupus 2001 10 5 346 351 2-s2.0-0034993766 10.1191/096120301667475689 (Pubitemid 32520241)
186. Zhao D., Ogawa H., Wang X., Cameron G. S., Baty D. E., Dlott J. S., Triplett D. A., Oxidized low-density lipoprotein and autoimmune antibodies in patients with antiphospholipid syndrome with a history of thrombosis. American Journal of Clinical Pathology 2001 116 5 760 767 2-s2.0-0035736459 10.1309/1RYQ-Q2AJ-CKF7-YCDE (Pubitemid 34453219)
187. Amengual O., Atsumi T., Khamashta M. A., Tinahones F., Hughes G. R. V., Autoantibodies against oxidized low-density lipoprotein in antiphospholipid syndrome. Rheumatology 1997 36 9 964 968 2-s2.0-0030867292
188. Orchard T. J., Virella G., Forrest K. Y.-Z., Evans R. W., Becker D. J., Lopes-Virella M. F., Antibodies to oxidized LDL predict coronary artery disease in type 1 diabetes: a nested case-control study from the Pittsburgh epidemiology of diabetes complications study. Diabetes 1999 48 7 1454 1458 2-s2.0-0033030997 10.2337/diabetes.48.7.1454 (Pubitemid 29297310)
189. Bellomo G., Maggi E., Poli M., Agosta F. G., Bollati P., Finardi G., Antoantibodies against oxidatively modified low-density lipoproteins in NIDDM. Diabetes 1995 44 1 60 66 2-s2.0-0028985195
190. O'Byrne D., Devaraj S., Islam K. N., Collazo R., McDonald L., Grundy S., Jialal I., Low-density lipoprotein (LDL)-induced monocyte-endothelial cell adhesion, soluble cell adhesion molecules, and autoantibodies to oxidized-LDL in chronic renal failure patients on dialysis therapy. Metabolism 2001 50 2 207 215 2-s2.0-0035116227 10.1053/meta.2001.19486 (Pubitemid 32170835)
191. Itabe H., Takeshima E., Iwasaki H., Kimura J., Yoshida Y., Imanaka T., Takano T., A monoclonal antibody against oxidized lipoprotein recognizes foam cells in atherosclerotic lesions. Complex formation of oxidized phosphatidylcholines and polypeptides. Journal of Biological Chemistry 1994 269 21 15274 15279 2-s2.0-0028321941
192. Boyd H. C., Gown A. M., Wolfbauer G., Chait A., Direct evidence for a protein recognized by a monoclonal antibody against oxidatively modified LDL in atherosclerotic lesions from a Watanabe heritable hyperlipidemic rabbit. The American Journal of Pathology 1989 135 5 815 825 2-s2.0-0024381339 (Pubitemid 20009491)
193. Shoenfeld Y., Wu R., Dearing L. D., Matsuura E., Are anti-oxidized low-density lipoprotein antibodies pathogenic or protective? Circulation 2004 110 17 2552 2558 2-s2.0-7544229779 10.1161/01.CIR.0000143225.07377.EA (Pubitemid 39453000)
194. Stemme S., Faber B., Holm J., Wiklund O., Witztum J. L., Hansson G. K., T lymphocytes from human atherosclerotic plaques recognize oxidized low density lipoprotein. Proceedings of the National Academy of Sciences of the United States of America 1995 92 9 3893 3897 2-s2.0-0029053557
195. Björkerud S., Björkerud B., Apoptosis is abundant in human atherosclerotic lesions, especially in inflammatory cells (macrophages and T cells), and may contribute to the accumulation of gruel and plaque instability. The American Journal of Pathology 1996 149 2 367 380 2-s2.0-0030055903 (Pubitemid 26256326)
196. Steinbrecher U. P., Parthasarathy S., Leake D. S., Modification of low density lipoprotein by endothelial cells involves lipid peroxidation and degradation of low density lipoprotein phospholipids. Proceedings of the National Academy of Sciences of the United States of America 1984 81 12 3883 3887 2-s2.0-0000061171 (Pubitemid 14087823)
197. Hörkkö S., Olee T., Mo L., Branch D. W., Woods V. L. Jr., Palinski W., Chen P. P., Witztum J. L., Anticardiolipin antibodies from patients with the antiphospholipid antibody syndrome recognize epitopes in both β 2-glycoprotein 1 and oxidized low-density lipoprotein. Circulation 2001 103 7 941 946 2-s2.0-0035916304 (Pubitemid 32183798)
198. Hörkkö S., Miller E., Dudl E., Reaven P., Curtiss L. K., Zvaifler N. J., Terkeltaub R., Pierangeli S. S., Branch D. W., Palinski W., Witztum J. L., Antiphospholipid antibodies are directed against epitopes of oxidized phospholipids: recognition of cardiolipin by monoclonal antibodies to epitopes of oxidized low density lipoprotein. Journal of Clinical Investigation 1996 98 3 815 825 2-s2.0-0038871839 (Pubitemid 26349187)
199. Tuominen A., Miller Y. I., Hansen L. F., Kesäniemi Y. A., Witztum J. L., Hörkkö S., A natural antibody to oxidized cardiolipin binds to oxidized low-density lipoprotein, apoptotic cells, and atherosclerotic lesions. Arteriosclerosis, Thrombosis, and Vascular Biology 2006 26 9 2096 2102 2-s2.0-33747379849 10.1161/01.ATV.0000233333.07991.4a (Pubitemid 44253794)
200. Vaarala O., Alfthan G., Jauhiainen M., Leirisalo-Repo M., Aho K., Palosuo T., Crossreaction between antibodies to oxidised low-density lipoprotein and to cardiolipin in systemic lupus erythematosus. The Lancet 1993 341 8850 923 925 2-s2.0-0027457735 10.1016/0140-6736(93)91213-6 (Pubitemid 23109111)
201. Ahmad S., Habib S., Moinuddin, Ali A., Preferential recognition of epitopes on AGE-IgG by the autoantibodies in rheumatoid arthritis patients. Human Immunology 2013 74 1 23 27 10.1016/j.humimm.2012.10.008
202. Lundberg K., Nijenhuis S., Vossenaar E. R., Palmblad K., van Venrooij W. J., Klareskog L., Zendman A. J., Harris H. E., Citrullinated proteins have increased immunogenicity and arthritogenicity and their presence in arthritic joints correlates with disease severity. Arthritis Research & Therapy 2005 7 3 R458 R467 2-s2.0-27744515706
203. Kuhn K. A., Kulik L., Tomooka B., Braschler K. J., Arend W. P., Robinson W. H., Holers V. M., Antibodies against citrullinated proteins enhance tissue injury in experimental autoimmune arthritis. Journal of Clinical Investigation 2006 116 4 961 973 2-s2.0-33645511657 10.1172/JCI25422
204. Clavel C., Nogueira L., Laurent L., Iobagiu C., Vincent C., Sebbag M., Serre G., The rheumatoid arthritis-specific autoantibodies to citrullinated proteins complexed with fibrin (ogen) induce macrophage secretion of TNF-alpha through engagement of Fc gamma RIIA. Annals of the Rheumatic Diseases 2008 67 supplement 1 A2
205. Laurent L., Clavel C., Lemaire O., Anquetil F., Cornillet M., Zabraniecki L., Nogueira L., Fournié B., Serre G., Sebbag M., Fc γ receptor profile of monocytes and macrophages from rheumatoid arthritis patients and their response to immune complexes formed with autoantibodies to citrullinated proteins. Annals of the Rheumatic Diseases 2011 70 6 1052 1059 2-s2.0-79955824880 10.1136/ard.2010.142091
206. Westman E., Lundberg K., Harris H. E., Arthritogenicity of collagen type II is increased by chlorination. Clinical & Experimental Immunology 2006 145 2 339 345 2-s2.0-33745956288 10.1111/j.1365-2249.2006.03129.x (Pubitemid 44060125)
207. Uesugi M., Yoshida K., Jasin H. E., Inflammatory properties of IgG modified by oxygen radicals and peroxynitrite. The Journal of Immunology 2000 165 11 6532 6537 2-s2.0-0034544448
208. Shahab U., Ahmad S., Moinuddin M., Dixit K., Habib S., Alam K., Ali A., Hydroxyl radical modification of collagen type II increases its arthritogenicity and immunogenicity. PLoS ONE 2012 7 2 2-s2.0-84856526075 10.1371/journal.pone. 0031199 e31199
209. Kummu O., Turunen S. P., Wang C., Lehtimäki J., Veneskoski M., Kastarinen H., Koivula M. K., Risteli J., Kesäniemi Y. A., Hörkkö S., Carbamyl adducts on low-density lipoprotein induce IgG response in L D L R-/-mice and bind plasma autoantibodies in humans under enhanced carbamylation. Antioxidants & Redox Signaling 2013 19 10 1047 1062 10.1089/ars.2012.4535
210. Arend W. P., Firestein G. S., Pre-rheumatoid arthritis: predisposition and transition to clinical synovitis. Nature Reviews Rheumatology 2012 8 10 573 586 10.1038/nrrheum.2012.134
211. Scinocca M. J., Immune responses to homocitrullinated protein/peptide in rheumatoid arthritis. The University of Western Ontario-Electronic Thesis and Dissertation Repository, 2012, http://ir.lib.uwo.ca/etd/774/
212. Nielen M. M., van Schaardenburg D., Reesink H. W., van de Stadt R. J., van der Horst-Bruinsma I. E., de Koning M. H. M. T., Habibuw M. R., Vandenbroucke J. P., Dijkmans B. A. C., Specific autoantibodies precede the symptoms of rheumatoid arthritis: a study of serial measurements in blood donors. Arthritis & Rheumatism 2004 50 2 380 386 2-s2.0-1042290337 10.1002/art.20018 (Pubitemid 38198821)
213. Auger I., Sebbag M., Vincent C., Balandraud N., Guis S., Nogueira L., Svensson B., Cantagrel A., Serre G., Roudier J., Influence of HLA-DR genes on the production of rheumatoid arthritis-specific autoantibodies to citrullinated fibrinogen. Arthritis & Rheumatism 2005 52 11 3424 3432 2-s2.0-27744514543 10.1002/art.21391 (Pubitemid 41612208)
214. Ireland J., Herzog J., Unanue E. R., Cutting edge: unique T cells that recognize citrullinated peptides are a feature of protein immunization. The Journal of Immunology 2006 177 3 1421 1425 2-s2.0-33746214870 (Pubitemid 44092474)
215. van der Woude D., Rantapää-Dahlqvist S., Ioan-Facsinay A., Onnekink C., Schwarte C. M., Verpoort K. N., Drijfhout J. W., Huizinga T. W. J., Toes R. E. M., Pruijn G. J. M., Epitope spreading of the anti-citrullinated protein antibody response occurs before disease onset and is associated with the disease course of early arthritis. Annals of the Rheumatic Diseases 2010 69 8 1554 1561 2-s2.0-77955464379 10.1136/ard.2009.124537
216. Brink M., Hansson M., Mathsson L., Jakobsson P. J., Holmdahl R., Hallmans G., Stenlund H., Rönnelid J., Klareskog L., Rantapää-Dahlqvist S., Multiplex analyses of antibodies against citrullinated peptides in individuals prior to development of rheumatoid arthritis. Arthritis & Rheumatism 2013 65 4 899 910 10.1002/art.37835
217. Kokkonen H., Mullazehi M., Berglin E., Hallmans G., Wadell G., Rönnelid J., Rantapää-Dahlqvist S., Antibodies of IgG, IgA and IgM isotypes against cyclic citrullinated peptide precede the development of rheumatoid arthritis. Arthritis Research & Therapy 2011 13 1, article R13 2-s2.0-79551517665 10.1186/ar3237
218. van der Woude D., Rantapää-Dahlqvist S., Ioan-Facsinay A., Onnekink C., Schwarte C. M., Verpoort K. N., Drijfhout J. W., Huizinga T. W. J., Toes R. E. M., Pruijn G. J. M., Epitope spreading of the anti-citrullinated protein antibody response occurs before disease onset and is associated with the disease course of early arthritis. Annals of the Rheumatic Diseases 2010 69 8 1554 1561 2-s2.0-77955464379 10.1136/ard.2009.124537
219. Verpoort K. N., Cheung K., Ioan-Facsinay A., van der Helm-van Mil A. H. M., de Vries-Bouwstra J. K., Allaart C. F., Drijfhout J. W., de Vries R. R. P., Breedveld F. C., Huizinga T. W. J., Pruijn G. J. M., Toes R. E. M., Fine
220. Suwannalai P., Scherer H. U., van der Woude D., Ioan-Facsinay A., Jol-van der Zijde C. M., van Tol M. J. D., Drijfhout J. W., Huizinga T. W. J., Toes R. E. M., Trouw L. A., Anti-citrullinated protein antibodies have a low avidity compared with antibodies against recall antigens. Annals of the Rheumatic Diseases 2011 70 2 373 379 2-s2.0-78751701595 10.1136/ard.2010.135509
221. Suwannalai P., van de Stadt L. A., Radner H., Steiner G., El-Gabalawy H. S., Zijde C. M. J.-V. D., van Tol M. J., van Schaardenburg D., Huizinga T. W. J., Toes R. E. M., Trouw L. A., Avidity maturation of anti-citrullinated protein antibodies in rheumatoid arthritis. Arthritis & Rheumatism 2012 64 5 1323 1328 2-s2.0-84860442529 10.1002/art.33489
222. Suwannalai P., Britsemmer K., Knevel R., Scherer H. U., Levarht E. W., van der Helm-van Mil A. H., van Schaardenburg D., Huizinga T. W., Toes R. E., Trouw L. A., Low-avidity anticitrullinated protein antibodies (ACPA) are associated with a higher rate of joint destruction in rheumatoid arthritis. Annals of the Rheumatic Diseases 2014 73 1 270 276 10.1136/annrheumdis-2012- 202615
223. Verpoort K. N., Jol-van der Zijde C. M., Papendrecht-van der Voort E. A. M., Ioan-Facsinay A., Drijfhout J. W., van Tol M. J. D., Breedveld F. C., Huizinga T. W. J., Toes R. E. M., Isotype distribution of anti-cyclic citrullinated peptide antibodies in undifferentiated arthritis and rheumatoid arthritis reflects an ongoing immune response. Arthritis & Rheumatism 2006 54 12 3799 3808 2-s2.0-33845622856 10.1002/art.22279 (Pubitemid 44955880)
224. Scherer H. U., van der Woude D., Ioan-Facsinay A., El Bannoudi H., Trouw L. A., Wang J., Häupl T., Burmester G.-R., Deelder A. M., Huizinga T. W. J., Wuhrer M., Toes R. E. M., Glycan profiling of anti-citrullinated protein antibodies isolated from human serum and synovial fluid. Arthritis & Rheumatism 2010 62 6 1620 1629 2-s2.0-77952911607 10.1002/art.27414
225. Roth E., Stenberg P., Book C., Sjöberg K., Antibodies against transglutaminases, peptidylarginine deiminase and citrulline in rheumatoid arthritis-new pathways to epitope spreading. Clinical and Experimental Rheumatology 2006 24 1 12 18 2-s2.0-33645088938
226. Vanderlugt C. L., Miller S. D., Epitope spreading in immune-mediated diseases: implications for immunotherapy. Nature Reviews Immunology 2002 2 2 85 95 2-s2.0-0036481263 (Pubitemid 37323232)
227. van de Stadt L. A., van der Horst A. R., de Koning M. H. M. T., Bos W. H., Jan Wolbink G., van de Stadt R. J., Pruijn G. J. M., Dijkmans B. A. C., van Schaardenburg D., Hamann D., The extent of the anti-citrullinated protein antibody repertoire is associated with arthritis development in patients with seropositive arthralgia. Annals of the Rheumatic Diseases 2011 70 1 128 133 2-s2.0-78650677084 10.1136/ard.2010.132662
228. van de Stadt L. A., de Koning M. H. M. T., van de Stadt R. J., Wolbink G., Dijkmans B. A. C., Hamann D., van Schaardenburg D., Development of the anti-citrullinated protein antibody repertoire prior to the onset of rheumatoid arthritis. Arthritis & Rheumatism 2011 63 11 3226 3233 2-s2.0-80155127957 10.1002/art.30537
229. Murray F., Israelsson L., Steen J., Amara K., Shi J., Klareskog L., Trouw L., Malmström V., A5.14 Homocitrulline-reactive antibodies can be generated from synovial B-cells from ACPA-negative RA patients. Annals of the Rheumatic Diseases 2013 72 supplement 1, article A35 10.1136/annrheumdis-2013- 203219.14
230. Schuerwegh A., Ioan-Facsinay A., Dorjée A. L., Roos J., Bajema I. M., van der Voort E. I. H., Huizinga T. W. J., Toes R. E. M., Evidence for a functional role of IgE anticitrullinated protein antibodies in rheumatoid arthritis. Proceedings of the National Academy of Sciences of the United States of America 2010 107 6 2586 2591 2-s2.0-77249097859 10.1073/pnas.0913054107
231. Lakos G., Soós L., Fekete A., Szabó Z., Zeher M., Horváth I. F., Dankó K., Kapitány A., Gyetvai A., Szegedi G., Szekanecz Z., Anti-cyclic citrullinated peptide antibody isotypes in rheumatoid arthritis: association with disease duration, rheumatoid factor production and the presence of shared epitope. Clinical and Experimental Rheumatology 2008 26 2 253 260 2-s2.0-43549111127 (Pubitemid 351673956)
232. Svärd A., Kastbom A., Söderlin M. K., Reckner-Olsson Å., Skogh T., A comparison between IgG- and IgA-class antibodies to cyclic citrullinated peptides and to modified citrullinated vimentin in early rheumatoid arthritis and very early arthritis. The Journal of Rheumatology 2011 38 7 1265 1272 2-s2.0-79960013558 10.3899/jrheum.101086
233. Svärd A., Kastbom A., Reckner-Olsson Å., Skogh T., Presence and utility of IgA-class antibodies to cyclic citrullinated peptides in early rheumatoid arthritis: the Swedish TIRA project. Arthritis Research & Therapy 2008 10 4, article R75 2-s2.0-48249157330 10.1186/ar2449
234. van der Woude D., Syversen S. W., van der Voort E. I. H., Verpoort K. N., Goll G. L., van der Linden M. P. M., van der Helm-van Mil A. H. M., van der Heijde D. M. F. M., Huizinga T. W. J., Kvien T. K., Toes R. E. M., The ACPA isotype profile reflects long-term radiographic progression in rheumatoid arthritis. Annals of the Rheumatic Diseases 2010 69 6 1110 1116 2-s2.0-77953702948 10.1136/ard.2009.116384
235. Suwannalai P., Trouw L. A., Toes R. E. M., Huizinga T. W. J., Anti-citrullinated protein antibodies (ACPA) in early rheumatoid arthritis. Modern Rheumatology 2012 22 1 15 20 2-s2.0-79959794021 10.1007/s10165-011-0486-8
236. Arnold J. N., Wormald M. R., Sim R. B., Rudd P. M., Dwek R. A., The impact of glycosylation on the biological function and structure of human immunoglobulins. Annual Review of Immunology 2007 25 21 50 10.1146/annurev. immunol.25.022106.141702 (Pubitemid 46697901)
237. Kempers A. C., Scherer H. U., Rombouts Y., Ewing E., van de Stadt L. A., Selman M. H. J., Deelder A. M., Huizinga T. W. J., Wuhrer M., van Schaardenburg D., Toes R. E. M., A1.1 Anti-citrullinated protein antibody specific Fc glycosylation patterns in arthralgia patients. Annals of the Rheumatic Diseases 2013 72 supplement 1, article A1 10.1136/annrheumdis-2013-203214.1
238. van de Geijn F. E., Wuhrer M., Selman M. H. J., Willemsen S. P., de Man Y. A., Deelder A. M., Hazes J. M. W., Dolhain R. J. E. M., Immunoglobulin G galactosylation and sialylation are associated with pregnancy-induced improvement of rheumatoid arthritis and the postpartum flare: results from a large prospective cohort study. Arthritis Research & Therapy 2009 11 6, article R193 2-s2.0-77952487132 10.1186/ar2892
239. Ercan A., Cui J., Hazen M. M., Batliwalla F., Royle L., Rudd P. M., Coblyn J. S., Shadick N., Weinblatt M. E., Gregersen P., Lee D. M., Nigrovic P. A., Hypogalactosylation of serum N-glycans fails to predict clinical response to methotrexate and TNF inhibition in rheumatoid arthritis. Arthritis Research & Therapy 2012 14 2, article R43 2-s2.0-84857672126 10.1186/ar3756
240. Vos K., Thurlings R. M., Wijbrandts C. A., van Schaardenburg D., Gerlag D. M., Tak P. P., Early effects of rituximab on the synovial cell infiltrate in patients with rheumatoid arthritis. Arthritis & Rheumatism 2007 56 3 772 778 2-s2.0-33947102642 10.1002/art.22400 (Pubitemid 46399424)
241. Reparon-Schuijt C. C., van Esch W. J., van Kooten C., Schellekens G. A., de Jong B. A., van Venrooij W. J., Breedveld F. C., Verweij C. L., Secretion of anti-citrulline-containing peptide antibody by B lymphocytes in rheumatoid arthritis. Arthritis & Rheumatism 2001 44 1 41 47 (Pubitemid 32113116)
242. Reparon-Schuijt C. C., van Esch W. J., van Kooten C., Levarht E. W., Breedveld F. C., Verweij C. L., Functional analysis of rheumatoid factor-producing B cells from the synovial fluid of rheumatoid arthritis patients. Arthritis & Rheumatism 1998 41 12 2211 2220 (Pubitemid 29009380)
243. Miller F. W., Alfredsson L., Costenbader K. H., Kamen D. L., Nelson L. M., Norris J. M., de Roos A. J., Epidemiology of environmental exposures and human autoimmune diseases: findings from a National Institute of Environmental Health Sciences Expert Panel Workshop. Journal of Autoimmunity 2012 39 4 259 271 10.1016/j.jaut.2012.05.002
244. Stolt P., Yahya A., Bengtsson C., Källberg H., Rönnelid J., Lundberg I., Klareskog L., Alfredsson L., Lindahl G., Sverdrup B., Hellström H., Weitoft T., Lindell B., Nordmark B., Bratt J., Hafström I., Leden I., Löfström B., Bengtsson A., Skogh T., Lindqvist E., Jacobsson L., Huddénius K., Lindström C., Teleman A., Baecklund E., Knight A., Svernell O., Silica exposure among male current smokers is associated with a high risk of developing ACPA-positive rheumatoid arthritis. Annals of the Rheumatic Diseases 2010 69 6 1072 1076 2-s2.0-77953694440 10.1136/ard.2009.114694
245. Stolt P., Källberg H., Lundberg I., Sjögren B., Klareskog L., Alfredsson L., Silica exposure is associated with increased risk of developing rheumatoid arthritis: results from the Swedish EIRA study. Annals of the Rheumatic Diseases 2005 64 4 582 586 2-s2.0-16344369383 10.1136/ard.2004.022053 (Pubitemid 40469088)
246. Turner S., Cherry N., Rheumatoid arthritis in workers exposed to silica in the pottery industry. Occupational and Environmental Medicine 2000 57 7 443 477 2-s2.0-0034044779 10.1136/oem.57.7.443 (Pubitemid 30410704)
247. Speck-Hernandez C. A., Montoya-Ortiz G., Silicon, a possible link between environmental exposure and autoimmune diseases: the case of rheumatoid arthritis. Arthritis 2012 2012 11 604187 10.1155/2012/604187
248. Klareskog L., Padyukov L., Lorentzen J., Alfredsson L., Mechanisms of disease: genetic susceptibility and environmental triggers in the development of rheumatoid arthritis. Nature Clinical Practice Rheumatology 2006 2 8 425 433 2-s2.0-33746940384 10.1038/ncprheum0249 (Pubitemid 44203826)
249. Lee H.-S., Irigoyen P., Kern M., Lee A., Batliwalla F., Khalili H., Wolfe F., Lum R. F., Massarotti E., Weisman M., Bombardier C., Karlson E. W., Criswell L. A., Vlietinck R., Gregersen P. K., Interaction between smoking, the shared epitope, and anti-cyclic citrullinated peptide: a mixed picture in three large North American rheumatoid arthritis cohorts. Arthritis & Rheumatism 2007 56 6 1745 1753 2-s2.0-34447509669 10.1002/art.22703 (Pubitemid 47110374)
250. Klareskog L., Padyukov L., Rönnelid J., Alfredsson L., Genes, environment and immunity in the development of rheumatoid arthritis. Current Opinion in Immunology 2006 18 6 650 655 2-s2.0-33750367268 10.1016/j.coi.2006. 06.004 (Pubitemid 44635174)
251. Reparon-Schuijt C. C., van Esch W. J., van Kooten C., Ezendam N. P., Levarht E. W., Breedveld F. C., Verweij C. L., Presence of a population of CD20+, CD38- B lymphocytes with defective proliferative responsiveness in the synovial compartment of patients with rheumatoid arthritis. Arthritis & Rheumatism 2001 44 9 2029 2037 (Pubitemid 33644045)
252. Edwards J. C., Cambridge G., B-cell targeting in rheumatoid arthritis and other autoimmune diseases. Nature Reviews Immunology 2006 6 5 394 403 2-s2.0-33646362290 10.1038/nri1838
253. Takemura S., Klimiuk P. A., Braun A., Goronzy J. J., Weyand C. M., T cell activation in rheumatoid synovium is B cell dependent. The Journal of Immunology 2001 167 8 4710 4718 2-s2.0-0035888030 (Pubitemid 32954353)
254. Tidén A.-K., Sjögren T., Svensson M., Bernlind A., Senthilmohan R., Auchère F., Norman H., Markgren P.-O., Gustavsson S., Schmidt S., Lundquist S., Forbes L. V., Magon N. J., Paton L. N., Jameson G. N. L., Eriksson H., Kettle A. J., 2-Thioxanthines are mechanism-based inactivators of myeloperoxidase that block oxidative stress during inflammation. Journal of Biological Chemistry 2011 286 43 37578 37589 2-s2.0-80054798514 10.1074/jbc.M111.266981
255. Segelmark M., Persson B., Hellmark T., Wieslander J., Binding and inhibition of myeloperoxidase (MPO): a major function of ceruloplasmin? Clinical & Experimental Immunology 1997 108 1 167 174 2-s2.0-0030894460 (Pubitemid 27140345)